

Fasting Bioavailability Study - 1.25 mg, Continued




Table 22
 Mean Plasma Concentrations of Free Estrone and Equilin after a 1 x 1.25 mg Dose Under Fasting Conditions

Time After Dose (hr)	Free Estrone (Baseline Corrected)		Free Equilin	
	Test Formulation (Cenestin™) Duramed pg/mL (CV%)	Reference Formulation (Premarin®) Wyeth-Ayerst pg/mL (CV%)	Test Formulation (Cenestin™) Duramed pg/mL (CV%)	Reference Formulation (Premarin®) Wyeth-Ayerst pg/mL (CV%)
0	0.00	0.00	0.00	0.00
1.5	6.07 (112.0)	0.99 (158.0)	7.23 (80.5)	0.00
3.0	22.76 (59.3)	4.54 (110.5)	18.23 (53.1)	3.32 (188.8)
4.5	56.13 (46.9)	25.60 (81.4)	28.42 (44.9)	15.06 (103.6)
6.0	62.88 (45.7)	40.64 (61.7)	29.70 (42.6)	24.23 (61.4)
7.5	66.15 (42.9)	52.20 (58.1)	30.90 (45.3)	29.77 (51.9)
9.0	69.06 (42.1)	60.95 (53.6)	29.81 (43.8)	30.89 (46.9)
10.5	62.84 (43.8)	59.63 (52.5)	26.40 (42.7)	27.16 (40.6)
12	58.43 (43.4)	55.03 (50.9)	23.21 (45.6)	24.31 (44.9)
14	50.50 (40.3)	51.75 (46.9)	19.61 (42.3)	22.81 (47.8)
16	45.57 (45.7)	44.77 (48.7)	18.07 (47.1)	20.59 (49.0)
24	33.70 (45.1)	35.92 (46.9)	9.11 (81.7)	10.75 (69.5)
32	19.71 (58.3)	20.21 (57.1)	4.87 (120.4)	5.81 (98.3)
40	11.41 (72.0)	11.36 (73.7)	1.87 (203.8)	2.18 (168.2)
48	10.28 (61.5)	9.85 (66.9)	0.38 (475.5)	0.60 (349.2)
60	2.32 (162.3)	2.76 (148.6)	0.10 (793.7)	0.08 (800.0)
72	4.72 (142.7)	3.38 (98.8)	0.00	0.00

06-057

.32

030125

Effect-of-Food Study - 0.625 mg, Continued

Table 26
 Mean Pharmacokinetic Parameters after a 2 x 0.625 mg Dose
 under Non-Fasting Conditions
 Total Estrone (Baseline Corrected)

Pharmacokinetic Parameter	Test Formulation (Cenesin™) Duramed Mean (CV%)	Reference Formulation (Premarin®) Wyeth-Ayerst Mean (CV%)	Ratio of Least Square Means (%)
AUC(0-4) (Measured) (ng ² hr/mL)	77.44 (31.9)	79.47 (32.7)	-
AUC(0-4) (Geometric) (ng ² hr/mL)	73.69	75.70	97.3
AUC(0-72) (Measured) (ng ² hr/mL)	77.44 (31.9)	79.47 (32.7)	-
AUC(0-72) (Geometric) (ng ² hr/mL)	73.69	75.70	97.3
AUC(0-∞) (Measured) (ng ² hr/mL)	83.22 (30.0)	85.71 (32.4)	-
AUC(0-∞) (Geometric) (ng ² hr/mL)	78.26	80.04	97.3
C _{max} (Measured) (ng/mL)	4.584 (37.3)	4.418 (30.4)	-
C _{max} (Geometric) (ng/mL)	4.277	4.225	101.2
k _{el} (Measured) (1/hr)	0.0525 (18.7)	0.0493 (30.9)	-
t _{1/2} (Measured) (hr)	13.62 (17.5)	17.31 (83.4)	-
T _{max} (Measured) (hr)	7.17 (32.5)	8.53 (30.3)	-

Table 27
 Mean Pharmacokinetic Parameters after a 2 x 0.625 mg Dose
 under Non-Fasting Conditions
 Total Equilin

Pharmacokinetic Parameter	Test Formulation (Cenesin™) Duramed Mean (CV%)	Reference Formulation (Premarin®) Wyeth-Ayerst Mean (CV%)	Ratio of Least Square Means (%)
AUC(0-4) (Measured) (ng ² hr/mL)	47.25 (29.1)	50.17 (33.0)	-
AUC(0-4) (Geometric) (ng ² hr/mL)	45.19	47.77	94.6
AUC(0-72) (Measured) (ng ² hr/mL)	47.58 (28.7)	50.49 (32.5)	-
AUC(0-72) (Geometric) (ng ² hr/mL)	45.57	48.14	94.7
AUC(0-∞) (Measured) (ng ² hr/mL)	48.39 (28.5)	51.32 (32.4)	-
AUC(0-∞) (Geometric) (ng ² hr/mL)	46.38	48.98	94.7
C _{max} (Measured) (ng/mL)	4.221 (32.1)	4.730 (30.7)	-
C _{max} (Geometric) (ng/mL)	4.020	4.505	89.2
k _{el} (Measured) (1/hr)	0.06612 (20.2)	0.06821 (19.3)	-
t _{1/2} (Measured) (hr)	10.33 (17.3)	10.52 (18.6)	-
T _{max} (Measured) (hr)	5.08 (20.6)	5.09 (35.2)	-

Continued on next page

06-065

33

Effect-of-Food Study - 0.625 mg, Continued

Table 29
 Mean Pharmacokinetic Parameters after a 2 x 0.625 mg Dose
 under Non-Fasting Conditions
 Free Estrone (Baseline Corrected)

Pharmacokinetic Parameter	Test Formulation (Cenestin™) Duramed Mean (CV%)	Reference Formulation (Premarin®) Wyeth-Ayerst Mean (CV%)	Ratio of Least Square Means (%)
AUC _(0-t) (Measured) (pg [*] hr/mL)	2616.7 (37.0)	2657.5 (41.0)	-
AUC _(0-t) (Geometric) (pg [*] hr/mL)	2441.0	2461.3	99.2
AUC ₍₀₋₇₂₎ (Measured) (pg [*] hr/mL)	2617.9 (37.1)	2657.7 (41.0)	-
AUC ₍₀₋₇₂₎ (Geometric) (pg [*] hr/mL)	2437.9	2461.7	99.0
C _{max} (Measured) (pg/mL)	114.8 (38.4)	117.9 (36.1)	-
C _{max} (Geometric) (pg/mL)	106.8	110.9	96.3
T _{max} (Measured) (hr)	9.22 (29.9)	9.11 (26.8)	-

Table 30
 Mean Pharmacokinetic Parameters after a 2 x 0.625 mg Dose
 under Non-Fasting Conditions
 Free Equilin

Pharmacokinetic Parameter	Test Formulation (Cenestin™) Duramed Mean (CV%)	Reference Formulation (Premarin®) Wyeth-Ayerst Mean (CV%)	Ratio of Least Square Means (%)
AUC _(0-t) (Measured) (pg [*] hr/mL)	890.0 (42.9)	930.5 (45.9)	-
AUC _(0-t) (Geometric) (pg [*] hr/mL)	812.49	844.84	96.2
AUC ₍₀₋₇₂₎ (Measured) (pg [*] hr/mL)	947.3 (40.2)	997.4 (42.6)	-
AUC ₍₀₋₇₂₎ (Geometric) (pg [*] hr/mL)	875.8	918.4	95.4
C _{max} (Measured) (pg/mL)	69.75 (43.1)	72.18 (33.0)	-
C _{max} (Geometric) (pg/mL)	64.29	69.03	93.1
T _{max} (Measured) (hr)	6.50 (30.7)	6.76 (34.1)	-

Continued on next page

06-067
 34

Effect-of-Food Study - 0.625 mg, Continued




Table 28

Mean Plasma Concentrations of Free Estrone and Equilin after a 2 x 0.625 mg Dose under Non-Fasting Conditions

Time After Dose (hr)	Free Estrone (Baseline Corrected)		Free Equilin	
	Test Formulation (Cenestin™) Duramed ng/mL (CV%)	Reference Formulation (Premarin®) Wyeth-Ayerst ng/mL (CV%)	Test Formulation (Cenestin™) Duramed ng/mL (CV%)	Reference Formulation (Premarin®) Wyeth-Ayerst ng/mL (CV%)
0	1.72 (134.0)	2.92 (91.9)	0.00	0.00
1.5	2.63 (138.3)	1.08 (234.9)	2.69 (232.6)	0.88 (424.3)
3.0	23.12 (82.6)	12.92 (141.5)	24.38 (74.7)	16.39 (121.0)
4.5	75.38 (55.4)	56.72 (77.5)	60.82 (41.7)	58.24 (55.0)
6.0	89.21 (55.1)	87.21 (59.0)	56.27 (51.9)	55.91 (42.7)
7.5	97.85 (40.1)	95.56 (43.3)	51.18 (36.4)	55.54 (33.5)
9.0	100.02 (40.3)	101.69 (42.0)	50.05 (33.3)	55.12 (38.6)
10.5	99.45 (35.3)	105.63 (40.8)	48.31 (35.4)	53.48 (38.2)
12	87.80 (35.0)	92.69 (37.7)	40.27 (33.5)	46.45 (34.9)
14	77.54 (38.0)	81.35 (38.6)	34.55 (28.7)	37.72 (30.5)
16	66.05 (40.4)	70.05 (45.1)	28.33 (34.8)	32.23 (39.9)
24	46.28 (32.5)	50.88 (40.4)	14.86 (60.2)	15.88 (58.4)
32	36.03 (44.9)	37.48 (54.0)	7.23 (122.9)	6.85 (125.9)
40	25.32 (54.4)	24.99 (41.6)	4.39 (147.5)	3.86 (168.5)
48	20.25 (49.1)	20.14 (50.5)	1.38 (296.7)	1.47 (291.3)
60	11.46 (63.5)	10.25 (61.4)	0.00	0.57 (424.3)
72	8.83 (62.2)	11.66 (69.4)	0.00	0.00

Continued on next page

06-066
 35

Duramed Pharmaceuticals, Inc.
 NDA 20-992 Synthetic Conjugated Estrogens
 Human Pharmacokinetics

Effect-of-Food Study- 1.25 mg, Continued

Table 33
 Mean Pharmacokinetic Parameters after a 1 x 1.25 mg Dose under Non-Fasting Conditions
 Total Estrone (Baseline Corrected)

	Mean Pharmacokinetic Parameters										
	InAUC _(0-∞) (pg*hr/ml)	InAUC _(0-t) (pg*hr/ml)	InAUC _(0-∞) (pg*hr/ml)	InC _{max} (pg/ml)	T _{max} (h)	k _a (1/h)	t _{1/2} (h)	AUC _(0-∞) (pg*hr/ml)	AUC _(0-t) (pg*hr/ml)	AUC _(0-∞) (pg*hr/ml)	C _{max} (pg/ml)
Duramed (A) CV% (n=22)	71557.37 32.2	71557.37 32.2	74355.86 33.8	3687.97 28.6	9.318 25.0	0.05614 29.4	13.256 25.7	74931.2 31.0	74931.2 31.0	78242.2 33.0	3825.59 27.1
Wyeth-Ayerst (I) CV% (n=22)	75716.77 31.9	75716.77 31.9	78621.24 33.1	3701.99 28.9	10.750 22.4	0.05591 25.3	13.082 22.7	79262.6 30.9	79262.6 30.9	82591.7 32.1	3840.05 26.8
Duramed (C) CV% (n=23)	68373.68 37.5	68195.34 37.7	71015.79 39.6	4458.53 28.6	7.043 31.7	0.05612 33.9	13.527 28.4	72704.0 36.2	72571.7 36.4	76029.9 38.4	4626.38 27.6
Wyeth-Ayerst (I) CV% (n=23)	65177.43 41.4	65144.41 41.5	67309.85 42.3	4234.58 36.6	9.261 39.0	0.05763 30.4	12.938 25.5	70012.6 37.2	69987.8 37.2	72514.4 37.9	4489.42 34.5
Least-Squares Means	69479.06	69501.49	72163.36	3641.15				73346.8	73359.6	76585.5	3797.72
Duramed (A)	75178.24	73202.24	78063.70	3611.67				78185.9	78201.9	81538.2	3721.43
Wyeth-Ayerst (I)	68323.61	68151.92	71017.59	4487.22				72925.2	72796.5	76333.5	4661.20
Duramed (C)	65851.78	65801.56	68009.66	4289.80				70892.8	70858.8	73430.8	4539.56
Ratio of Least-Squares Means ²	92.4	92.4	92.4	100.8				93.8	93.8	93.9	102.1
(A/B)%	101.7	102.0	101.6	81.1				100.6	100.8	100.3	81.5
(A/C)%	114.2	114.3	114.8	84.2				110.3	110.4	111.0	82.0

1. For In-transformed parameters, the antilog of the mean (i.e., the geometric mean) is reported.
 2. For In-transformed parameters, this ratio is defined as: $100 \cdot e^{(x-y)}$, where X and Y are the values of In-transformed least-squares means for Treatments A (test, fed), D (reference, fed), C (test, fasted) and D (reference, fasted), respectively.

Continued on next page

Effect-of-Food Study- 1.25 mg, Continued

Table 34
 Mean Pharmacokinetic Parameters after a 1 x 1.25 mg Dose under Non-Fasting Conditions
 Total Equilin

	Mean Pharmacokinetic Parameters										
	InAUC _{0-∞} (pg·hr/ml)	InAUC _{0-4h} (pg·hr/ml)	InAUC _{0-8h} (pg·hr/ml)	InC _{max} (pg/ml)	T _{max} (h)	k _d (1/h)	t _{1/2} (h)	AUC _{0-∞} (pg·hr/ml)	AUC _{0-4h} (pg·hr/ml)	AUC _{0-8h} (pg·hr/ml)	C _{max} (pg/ml)
Duramed (A) CV% (n=22)	44463.37 ¹ 41.7	44042.87 42.3	45267.10 41.4	3608.16 42.4	5.864 37.8	0.07072 18.3	10.144 20.0	47840.3 37.8	47474.4 38.3	48670.9 37.8	3889.76 38.3
Wyeth-Ayerst (B) CV% (n=22)	46626.24 43.1	46232.15 43.7	47520.07 42.7	3528.76 40.9	7.727 34.2	0.07255 21.8	9.919 21.5	50103.4 35.5	49765.5 35.9	51039.5 35.8	3772.87 35.0
Duramed (C) CV% (n=23)	41133.20 40.3	40773.20 40.6	42047.49 40.8	2862.87 31.0	5.870 36.9	0.07474 32.6	10.249 33.3	44056.8 37.0	43727.6 37.4	45130.6 37.7	3002.82 31.1
Wyeth-Ayerst (D) CV% (n=23)	41603.16 46.3	41225.39 46.8	42376.95 46.3	3158.15 47.3	8.478 46.4	0.07736 33.5	9.886 31.0	45522.9 42.7	45185.8 43.1	46366.8 42.7	3467.13 44.2
Least-Squares Means											
Duramed (A)	42896.04	42495.04	43643.63	3567.77				46239.9	45884.3	47034.3	3847.22
Wyeth-Ayerst (B)	45813.30	45417.40	46699.76	3373.86				49295.1	48955.9	50218.3	3623.10
Duramed (C)	40924.82	40366.08	41823.37	2882.03				44022.9	43694.8	45080.6	3022.81
Wyeth-Ayerst (D)	41732.56	41344.62	42561.67	3158.58				45919.3	45583.1	46813.4	3488.07
Ratio of											
Least-Squares Means ²											
(A/B)%	93.6	93.6	93.5	105.7				93.8	93.7	93.7	106.2
(A/C)%	104.8	104.8	104.4	123.8				105.0	105.0	104.3	127.3
(B/D)%	109.8	109.9	109.7	106.8				107.4	107.4	107.3	103.9

1 - For In-transformed parameters, the antilog of the mean (i.e., the geometric mean) is reported.
 2 - For In-transformed parameters, this ratio is defined as: $100 \cdot e^{(X-Y)}$, where X and Y are the values of In-transformed least-squares means for Treatments A (fast, fed), B (reference, fed), C (fast, fasted) and D (reference, fasted), respectively.

Continued on next page

06 - 076
 37

Effect-of-Food Study- 1.25 mg, Continued

Table 37

Mean Pharmacokinetic Parameters after a 1 x 1.25 mg Dose under Non-Fasting Conditions
 Free Estrone (Baseline Corrected)

	Mean Pharmacokinetic Parameters				
	lnAUC ₍₀₋₇₂₎ (pg*hr/mL)	lnC _{max} (pg/mL)	T _{max} (hr)	AUC ₍₀₋₇₂₎ (pg*hr/mL)	C _{max} (pg/mL)
Duramed (A)	2612.28 ¹	104.23	10.333	2724.1	107.66
CV% (n=21)	30.3	26.3	23.5	29.3	26.9
Wyeth-Ayerst (B)	2762.11	107.11	11.318	2854.6	111.52
CV% (n=22)	26.8	30.3	19.5	26.3	28.0
Duramed (C)	2453.18	110.13	8.381	2559.3	117.05
CV% (n=23)	31.9	38.0	27.6	27.9	35.0
Wyeth-Ayerst (D)	2296.23	100.29	10.090	2445.5	106.79
CV% (n=23)	37.7	38.1	23.3	37.7	36.1
Least-Squares Means					
Duramed (A)	2619.56	105.92		2719.2	109.40
Wyeth-Ayerst (B)	2792.38	109.10		2869.1	114.03
Duramed (C)	2470.50	112.03		2584.3	119.14
Wyeth-Ayerst (D)	2322.68	100.42		2473.0	106.53
Ratio of Least-Squares Means ²					
(A/B)%	93.3	97.1		94.8	95.9
(A/C)%	106.0	94.5		105.2	91.3
(B/D)%	120.2	108.6		116.0	107.0

Table 38

Mean Pharmacokinetic Parameters after a 1 x 1.25 mg Dose under Non-Fasting Conditions
 Free Equilin

	Mean Pharmacokinetic Parameters				
	lnAUC ₍₀₋₇₂₎ (pg*hr/mL)	lnC _{max} (pg/mL)	T _{max} (hr)	AUC ₍₀₋₇₂₎ (pg*hr/mL)	C _{max} (pg/mL)
Duramed (A)	787.99 ¹	58.72	7.762	850.4	63.71
CV% (n=21)	41.7	43.4	42.7	41.9	41.7
Wyeth-Ayerst (B)	847.10	57.55	9.167	911.3	61.56
CV% (n=21)	40.3	41.0	29.2	41.5	37.4
Duramed (C)	739.66	50.52	8.335	807.1	53.75
CV% (n=22)	43.4	39.0	36.3	47.3	36.2
Wyeth-Ayerst (D)	743.02	55.97	10.318	815.4	60.99
CV% (n=22)	46.0	43.5	55.3	47.3	45.3
Least-Squares Means					
Duramed (A)	788.76	60.04		850.0	65.43
Wyeth-Ayerst (B)	879.74	58.12		937.4	62.23
Duramed (C)	751.09	52.10		814.2	55.78
Wyeth-Ayerst (D)	750.22	55.34		813.6	60.381
Ratio of Least-Squares Means ²					
(A/B)%	89.7	103.3		90.7	105.1
(A/C)%	105.0	115.2		104.4	117.3
(B/D)%	117.3	104.1		114.5	103.1

- For ln-transformed parameters, the antilog of the mean (i.e., the geometric mean) is reported.
- For ln-transformed parameters, this ratio is defined as: $100 \cdot e^{(X-Y)}$, where X and Y are the values of ln-transformed least-squares means for Treatments A (test, fed), B (reference, fed), C (test, fasted) and D (reference, fasted), respectively.

06-079

38

Effect-of-Food Study- 1.25 mg, Continued




Table 35

Mean Plasma Concentrations of Free Estrone (Baseline Adjusted) after a 1 x 1.25 mg Dose under Non-Fasting Conditions

Time After Dose (hr)	Test Formulation (Cenestin™) Duramed pg/mL (CV%) Fed	Reference Formulation (Premarin®) Wyeth-Ayerst pg/mL (CV%) Fed	Test Formulation (Cenestin™) Duramed pg/mL (CV%) Fasted	Reference Formulation (Premarin®) Wyeth-Ayerst pg/mL (CV%) Fasted
0	0.00	0.00	0.00	0.00
1.5	1.67 (163.8)	0.79 (186.2)	13.90 (75.7)	3.90 (77.0)
3.0	14.52 (96.3)	3.51 (173.1)	35.88 (44.1)	9.93 (50.1)
4.5	57.34 (53.7)	21.83 (104.2)	80.00 (46.6)	44.85 (49.2)
6.0	73.03 (41.5)	43.82 (66.5)	85.56 (35.0)	66.99 (53.7)
7.5	88.07 (37.0)	69.87 (46.0)	95.89 (44.1)	79.40 (48.2)
9.0	94.88 (29.5)	89.31 (32.9)	95.32 (32.2)	92.80 (37.2)
10.5	98.01 (26.4)	100.91 (33.1)	91.96 (30.4)	94.78 (42.6)
12	90.46 (31.8)	99.36 (31.5)	86.68 (31.8)	95.22 (42.8)
14	82.64 (30.7)	91.11 (27.7)	73.16 (32.6)	80.61 (42.3)
16	71.13 (29.4)	80.38 (23.0)	65.57 (27.8)	68.05 (42.4)
24	54.58 (35.5)	64.19 (30.5)	48.96 (25.6)	46.98 (49.8)
32	41.12 (33.4)	44.63 (30.9)	36.36 (33.0)	32.00 (54.3)
40	29.94 (39.3)	33.68 (36.7)	24.94 (41.4)	26.26 (49.1)
48	21.90 (47.5)	25.35 (37.8)	18.73 (38.8)	13.27 (45.5)
60	11.61 (78.8)	12.05 (62.5)	9.46 (85.8)	8.46 (84.5)
72	9.67 (65.4)	9.68 (56.8)	7.31 (92.1)	7.42 (67.3)

Continued on next page

06-077

39

Effect-of-Food Study- 1.25 mg, Continued




Table 36
 Mean Plasma Concentrations of Free Equilin after a 1 x 1.25 mg Dose
 under Non-Fasting Conditions

Time After Dose (hr)	Test Formulation (Cenestin™) Duramed pg/mL (CV%) Fed	Reference Formulation (Premarin®) Wyeth-Ayerst pg/mL (CV%) Fed	Test Formulation (Cenestin™) Duramed pg/mL (CV%) Fasted	Reference Formulation (Premarin®) Wyeth-Ayerst pg/mL (CV%) Fasted
-48	0.00	0.00	0.00	0.00
-24	0.00	0.00	0.00	0.00
0	0.00	0.00	0.00	0.00
1.5	0.00	0.00	0.00	0.00
3.0	12.92 (112.9)	2.14 (353.8)	11.28 (90.7)	0.00
4.5	52.11 (59.2)	24.53 (111.6)	25.13 (59.5)	3.55 (201.5)
6.0	46.22 (45.2)	34.42 (69.1)	42.96 (45.5)	28.95 (101.4)
7.5	45.53 (36.1)	45.94 (46.1)	40.27 (37.7)	40.99 (61.1)
9.0	45.76 (32.5)	47.38 (39.7)	40.91 (37.6)	47.76 (53.8)
10.5	45.28 (40.0)	47.45 (43.4)	41.00 (33.3)	48.99 (41.0)
12	40.70 (34.8)	47.98 (34.6)	40.90 (37.4)	47.91 (47.1)
14	35.94 (42.7)	44.09 (37.9)	42.97 (44.4)	49.38 (48.3)
16	29.57 (41.0)	35.72 (35.8)	34.12 (45.8)	39.51 (40.8)
24	15.62 (67.0)	20.86 (46.7)	27.01 (42.2)	30.50 (42.4)
32	6.01 (136.7)	8.70 (102.1)	11.98 (89.4)	13.59 (81.1)
40	1.89 (251.2)	2.04 (256.7)	6.66 (131.7)	5.83 (160.5)
48	0.00	0.514 (458.3)	1.29 (336.9)	2.02 (261.0)
60	0.00	0.00	0.49 (469.0)	0.00
72	0.00	0.00	0.00	0.00

Continued on next page

06-078

410

2x0.625						
	C _{max} , ng/mL			AUC, ng·hr/mL		
	fed	fasted	% difference	fed	fasted	% difference
Total Estrone	4.584	4.43	3.48	77.44	69.89	10.8
Total Equiline	4.221	3.271	29.04	47.58	46.46	2.41
Free Estrone	0.115	0.085	35.79	2.618	1.749	49.68
Free Equiline	0.070	0.046	53.03	0.947	0.723	30.99

1x1.25						
	C _{max} , ng/mL			AUC, ng·hr/mL		
	fed	fasted	% difference	fed	fasted	% difference
Total Estrone	4.626	3.826	20.9	74.931	72.704	3.06
Total Equiline	3.88976	3.0028	29.54	47.474	43.726	8.57
Free Estrone	0.10766	0.11705	8.02	2.724	2.5593	6.44
Free Equiline	63.71	53.73	18.57	0.8504	0.8071	5.36

ATTACHMENT 5

Appendix

Individual
 dissolution

The following tables present individual tablet dissolution results for the 0.3-, 0.625-, 0.9, 1.25- and 2.5 mg Cenestin™ tablets.

Dissolution of Cenestin™ 0.3 mg Tablets, Lot X-0328

Percent Sodium Estrone Sulfate Released			
Tablet Id	2 Hour	5 Hour	8 Hour
1			
2			
3			
4			
5			
6			
7			
8			
9			
10			
11			
12			
Mean	37.5	73.9	93.9
Max	42.0	76.9	96.9
Min	34.6	70.1	88.7
%RSD	5.8	2.9	2.3

Dissolution of Cenestin™ 0.625 mg Tablets, Lot C-0005 (Biobatch)

Percent Sodium Estrone Sulfate Released			
Tablet Id	2 Hour	5 Hour	8 Hour
1			
2			
3			
4			
5			
6			
7			
8			
9			
10			
11			
12			
Mean	40.3	74.6	90.7
Max	43.5	76.5	93.4
Min	37.0	71.6	88.4
%RSD	5.2	2.2	1.5

Continued on next page

06-082

43

Appendix, Continued

Individual dissolution (continued)

Dissolution of Cenestin™ 0.9 mg Tablets, Lot X-0335

Tablet Id	Percent Sodium Estrone Sulfate Released		
	2 Hour	5 Hour	8 Hour
1			
2			
3			
4			
5			
6			
7			
8			
9			
10			
11			
12			
Mean	43.5	79.3	95.5
Max	46.0	81.4	96.5
Min	41.4	76.7	92.8
%RSD	4.0	2.0	1.1

Dissolution of Cenestin™ 1.25 mg Tablets, Lot C-0015 (Biobatch)

Tablet Id	Percent Sodium Estrone Sulfate Released			
	2 Hours	5 Hours	8 Hours	10 Hours
1				
2				
3				
4				
5				
6				
7				
8				
9				
10				
11				
12				
Mean	40.4	75.0	92.5	97.5
Max	41.6	67.9	94.6	99.7
Min	35.5	76.9	89.0	95.3
%RSD	4.7	3.2	1.3	1.4

Continued on next page

06-083

44

Appendix, Continued

Individual dissolution (continued)

Dissolution of Cenestin™ 2.5 mg Tablets, Lot S-0006

Tablet Id	Percent Sodium Estrone Sulfate Released			
	2 Hours	5 Hours	8 Hours	10 Hours
1				
2				
3				
4				
5				
6				
7				
8				
9				
10				
11				
12				
Mean	33.6	70.9	90.2	95.9
%RSD	5.4	2.1	1.6	1.7
Max	36.9	73.0	92.5	99.3
Min	31.6	68.3	88.2	93.6

Continued on next page


06-084

45

0. Dose Proportionality, Continued

Figure 6

Dissolution Profiles of Cenestin™ Tablets 0.3-, 0.625- and 0.9 mg




Continued on next page

06-029

46

F. Human Pharmacokinetics and Bioavailability Summary, Continued

Figure 7
Dissolution Profiles of Cenestin™ Tablets 1.25- and 2.5 mg



01-116

47

F. Human Pharmacokinetics and Bioavailability Summary, Continued

Table 4
Comparative Dissolution of 0.3-, 0.625- and 0.9 mg Cenestin™
Tablets

Cenestin™ 0.3 mg Tablets, Lot X-0328

Percent Sodium Estrone Sulfate Released			
	2 Hour	5 Hour	8 Hour
Mean	37.5	73.9	93.9
Max			
Min			
%RSD	5.8	2.9	2.3

Cenestin™ 0.625 mg Tablets, Lot C-0005 (Biobatch)

Percent Sodium Estrone Sulfate Released			
	2 Hour	5 Hour	8 Hour
Mean	40.3	74.6	90.7
Max			
Min			
%RSD	5.2	2.2	1.5

Cenestin™ 0.9 mg Tablets, Lot X-0335

Percent Sodium Estrone Sulfate Released			
	2 Hour	5 Hour	8 Hour
Mean	43.5	79.3	95.5
Max			
Min			
%RSD	4.0	2.0	1.1

Continued on next page